Home

Part of our AI Trading ecosystem

AI Trading Tool

The main AI trading tool page

AI Stock Analysis

4,600+ stocks analyzed

AI Stock Picks

Daily AI-generated picks

AI Stock Picker

Scan the universe for ideas

Stock Recommendations

Ranked AI research ideas

AI Trading Signals

Real-time momentum alerts

AI Stock Screener

Scan 4,600+ stocks live

Best AI Trading Tools

#1 pick: Stockinhood

How AI Trading Works

The technology explained

AI Stock Predictions

Multi-timeframe targets

SGRX

Bearish

Sangrix Inc.

Financial Services·Capital Markets

$2.18

Current Price

$1.79M

Market Cap

—

P/E Ratio

$166.71

52W High

$2.02

52W Low

Company Profile

CEO

Jing Jiao

Employees

5

Year Founded

2018

Headquarters

Singapore

Sector / Industry

Financial Services · Capital Markets

Key Statistics

Market Cap

$1.79M

Today's High

$3.44

Today's Low

$2.02

Open

$2.80

Previous Close

$2.21

52-Week High

$166.71

52-Week Low

$2.02

Today's Volume

3.66M

Avg. Volume

480.0K

Overnight Volume

125.0K

Shares Outstanding

821.0K

P/E Ratio

0.00

EPS

$-6.42

Beta

1.90

Dividend Yield

0.00%

Live market stats are a premium feature

These stats are from a cached snapshot. Unlock real-time data with lifetime access — $19.99.

Earnings History

Quarterly expected vs. actual performance

Q2 20262026-08-14
Missed -29%
EPS Est.-0.45
EPS Actual-0.58
Rev. Est.$0.02M
Rev. Actual$0.01M
Q1 20262026-05-15
Missed -20%
EPS Est.-0.60
EPS Actual-0.72
Rev. Est.$0.03M
Rev. Actual$0.01M
Q4 20252026-02-27
Missed -23%
EPS Est.-1.10
EPS Actual-1.35
Rev. Est.$0.05M
Rev. Actual$0.01M
Q3 20252025-11-14
Missed -19%
EPS Est.-1.80
EPS Actual-2.15
Rev. Est.$0.08M
Rev. Actual$0.02M

Earnings data is AI-compiled from public sources and may be delayed or approximate. Not financial advice.

Historical Price Chart

Price History

Chart data unavailable

AI Price Targets

Sangrix Inc. (formerly Bit Origin Ltd) recently completed a corporate rebranding and ticker transition to SGRX on Nasdaq. The company remains a high-risk micro-cap vehicle characterized by negligible trailing revenue ($39.5k), high historical cash burn leading to an accumulated deficit of roughly $88M, and ongoing regulatory headwinds. Technically, SGRX trades in a persistent downtrend marked by lower highs and high intraday slippage, with key support at $2.00. While minimal debt provides short-term balance sheet stability, poor ROIC (-26.2%) and dilution risk warrant a bearish stance.

7-Day Target

$2.02

-7.3%

30-Day Target

$1.75

-19.7%

6-Month Target

$1.30

-40.4%

AI Confidence

68%

Risk Level

High

Analyst Target

$26

Bull Case

The successful clinical validation of denifanstat as a first-in-class FASN inhibitor for MASH patients could capture a massive multi-billion dollar market, offering a superior safety and efficacy profile compared to existing treatments.

Bear Case

Failure to achieve primary endpoints in late-stage clinical trials or competitive pressure from GLP-1 agonists and other established MASH therapeutic pipelines could severely erode the company's valuation and long-term viability.

Key Catalysts

  • Top-line data readout from Phase 2b/3 clinical studies.
  • Potential strategic partnerships or licensing agreements with large-cap pharmaceutical companies.
  • Clearance from regulatory bodies for advanced trial designs.
  • Publication of positive long-term efficacy data in peer-reviewed journals.

Key Risks

  • •High dependence on the success of a single lead asset, denifanstat.
  • •Significant capital requirements for ongoing and future Phase 3 clinical trials.
  • •Intense competition from well-capitalized pharmaceutical giants in the MASH space.
  • •Potential for adverse safety signals or regulatory rejection by the FDA.

Company Overview

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for diseases resulting from dysfunctional lipid metabolic pathways. Their lead candidate, denifanstat, is an oral fatty acid synthase inhibitor currently in development for metabolic dysfunction-associated steatohepatitis (MASH).

Want Full Access to All Research?

Unlock unlimited AI stock analysis, market signals, and daily briefings for a one-time payment of $19.99.

30-day money-back guarantee • Secure payment by Square

SGRX Stock FAQ

What is the AI analysis for SGRX stock?

Stockinhood's AI generates multi-timeframe price targets for SGRX (Sangrix Inc.), including 7-day, 30-day, and 6-month outlooks based on market data, technical indicators, and news sentiment. These estimates are for informational purposes only and do not constitute financial advice.

Is SGRX stock a good investment?

Our AI assigns a sentiment signal (Bullish, Bearish, or Neutral) to SGRX based on multiple factors including price trends, momentum, and market conditions. The current AI signal is Bearish. This is AI-generated research, not financial advice — always consult a licensed advisor before investing.

What is the price target for SGRX?

The AI-generated price target for SGRX is based on multi-timeframe analysis and represents a hypothetical scenario, not a guarantee. The current price is $2.18. Price targets are educational estimates and should not be relied upon for investment decisions.

What are the risks of investing in SGRX?

High dependence on the success of a single lead asset, denifanstat. Significant capital requirements for ongoing and future Phase 3 clinical trials. Intense competition from well-capitalized pharmaceutical giants in the MASH space. Potential for adverse safety signals or regulatory rejection by the FDA. All risk analysis is informational only and not financial advice.

What sector is SGRX in?

Sangrix Inc. (SGRX) operates in the Financial Services sector, specifically the Capital Markets industry. This classification helps investors understand the company's business focus and compare it with peers in the same sector.